GlassScriptPhysician profile
Margaret B Dooley
NPI 1306811450
$550.43
in general payments reported to CMS, 2019-2025
13 companies · $161 in 2025
The $161 reported for 2025 was more than what a typical Obstetrics & Gynecology (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $101 · 2023: $56.09 · 2024: $233 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $449.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $89.21 | 2022-2025 | |
| Hologic Sales and Service, LLC | $60.61 | 2023-2024 | Myosure Tissue Removal Device, Aptima, Thinprep 2000 Processor |
| Bayer Healthcare Pharmaceuticals INC. | $57.53 | 2022 | |
| Astellas Pharma US INC | $54.88 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $48.10 | 2024 | Lynparza |
| Glaxosmithkline, LLC. | $46.15 | 2024 | Jemperli, Zejula |
| Genmab U.S., INC. | $43.61 | 2024-2025 | Tivdak |
| Caris Mpi, INC. | $39.60 | 2025 | Mi Cancer Seek |
| Tempus Ai, INC | $28.46 | 2025 | Xt Cdx |
| Takeda Pharmaceuticals U.S.A., INC. | $28.22 | 2025 | Gattex |
| Mayne Pharma Commercial LLC | $19.72 | 2023 | |
| Daiichi Sankyo INC. | $17.22 | 2025 | Enhertu |
| Vertex Pharmaceuticals Incorporated | $17.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Dooley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.